Vanda Pharmaceuticals Inc.VNDANASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 72% recommend buying.

Consensus Rating

Buy

18 analysts·Moderate coverage

72%

Rating Distribution

Strong Buy

00%

Buy

1372%

Hold

422%

Sell

16%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 74% higher.

Bear Case

$7.50

-3%

Consensus

$13.50

+74%

Bull Case

$22.00

+184%

Price Range18 analysts

Low

Consensus

High

$7.50

$22.00

Current Target

Current Price

$7.74

Upside to Target

$5.76

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.45(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+27.92%

EPS—

FY2028

Rev+17.61%

EPS—

FY2029

Rev+18.03%

EPS—

Earnings Surprises

Beat rate:67%(8/12 quarters)

Avg surprise:+13.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 5, 2026H.C. Wainwright

Vanda Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright

Target:$22.00

+166.7%from $8.25

Dec 31, 2025Jefferies

Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies

Target:$7.50

+6.7%from $7.03

Nov 5, 2025B.Riley Financial

B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy

Target:$11.00

+152.9%from $4.35

Jul 11, 2024Cantor Fitzgerald

Vanda Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald

Target:$11.00

+111.1%from $5.21

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance